ZyVersa Therapeutics, Inc.
ZyVersa Therapeutics is a clinical stage specialty biopharmaceutical company dedicated to developing first-in-class drugs for patients with inflammatory and kidney diseases. The company leverages advanced proprietary technologies, focusing on inflammasome space with its monoclonal antibody IC 100, and in kidney disease with its phase 2a candidate VAR 200. ZyVersa aims to improve health outcomes and quality of life for patients with high unmet medical needs.
Industries
Nr. of Employees
small (1-50)
ZyVersa Therapeutics, Inc.
Products
Inflammasome ASC‑targeting monoclonal antibody (IC 100)
A monoclonal antibody designed to bind adaptor ASC and inhibit intracellular ASC polymerization and extracellular ASC specks to block formation and spread of multiple inflammasomes; being developed for obesity-related metabolic complications and other inflammatory indications including CNS and cardiovascular diseases.
Cholesterol efflux mediator (2‑hydroxypropyl‑beta‑cyclodextrin; VAR 200)
A hydroxypropyl‑β‑cyclodextrin–based therapeutic designed to mediate removal of excess cholesterol and lipids from podocytes to protect glomerular structure, reduce proteinuria, and slow progression of kidney disease.
Inflammasome ASC‑targeting monoclonal antibody (IC 100)
A monoclonal antibody designed to bind adaptor ASC and inhibit intracellular ASC polymerization and extracellular ASC specks to block formation and spread of multiple inflammasomes; being developed for obesity-related metabolic complications and other inflammatory indications including CNS and cardiovascular diseases.
Cholesterol efflux mediator (2‑hydroxypropyl‑beta‑cyclodextrin; VAR 200)
A hydroxypropyl‑β‑cyclodextrin–based therapeutic designed to mediate removal of excess cholesterol and lipids from podocytes to protect glomerular structure, reduce proteinuria, and slow progression of kidney disease.
Services
Collaborations to advance discovery and development of therapeutics targeting inflammasomes and renal lipid biology (partnering on preclinical and clinical programs).
Collaborations to advance discovery and development of therapeutics targeting inflammasomes and renal lipid biology (partnering on preclinical and clinical programs).
Expertise Areas
- Inflammasome-targeted therapeutics
- Biologic drug discovery and development
- Renal disease therapeutics and podocyte biology
- Preclinical translational research
Key Technologies
- Monoclonal antibody therapeutics
- Cyclodextrin-based small-molecule therapeutics (hydroxypropyl‑β‑cyclodextrin)
- Inflammasome and ASC speck detection assays
- Preclinical kidney disease and podocyte models